prodchem
Aug 10, 2026
Lonza’s decision to sell its Capsules & Health Ingredients (CHI) business to U.S. private equity firm Lone Star Funds represents more than a portfolio restructuring. The transaction could also reshape ownership, investment priorities and supply-chain strategies across the global pharmaceutical and nutraceutical ingredients market.
Lonza agreed to divest CHI for an enterprise value of CHF 2.3 billion (approximately $3 billion). The transaction is expected to close in the second half of 2026, subject to regulatory approvals and the legal separation of the business.
Lonza will receive CHF 1.7 billion ($2.2 billion) in upfront proceeds while retaining a 40% stake in CHI. The company also expects total undiscounted proceeds of at least CHF 3 billion when future proceeds are included.
For pharmaceutical buyers, contract manufacturers and ingredient procurement teams, the transaction is important because CHI operates a broad international manufacturing network serving pharmaceutical and nutraceutical customers.
Lonza’s Capsules & Health Ingredients business includes several activities focused on pharmaceutical dosage forms, capsules and health ingredients.
Its portfolio includes hard empty capsules, including gelatin and plant-based Capsugel products, as well as specialized capsule technologies and solutions for pharmaceutical and nutraceutical applications.
The business also has manufacturing and development capabilities across multiple regions.
Its offering includes:
Hard empty capsules
Plant-based capsule technologies
Pharmaceutical dosage-form solutions
Health ingredients
Nutraceutical solutions
Encapsulation technologies
Development and formulation support
This makes CHI an important supplier within the broader pharmaceutical and nutritional products value chain.
The transaction is part of Lonza’s broader strategy to become a pure-play contract development and manufacturing organization (CDMO).
By separating CHI and other non-core assets, Lonza is concentrating its resources on pharmaceutical development and manufacturing services.
The company plans to use the upfront proceeds for additional organic growth opportunities and bolt-on acquisitions. It also intends to return CHF 500 million to shareholders through a share buyback after receiving the transaction proceeds.
This means the sale is not simply about exiting an asset. It is part of a broader reallocation of capital toward higher-growth pharmaceutical manufacturing opportunities.
For Lone Star Funds, the acquisition provides exposure to a business with established pharmaceutical and nutraceutical customers, specialized manufacturing capabilities and a global operating footprint.
The private equity firm has indicated that maintaining high standards of customer service and quality will be central to its strategy for CHI following closing.
The ownership change could nevertheless create opportunities for additional investment.
Private equity ownership often places greater emphasis on operational efficiency, targeted acquisitions, geographic expansion and portfolio optimization.
For customers, the important question will be how these priorities translate into manufacturing capacity, product development and commercial terms.
The transaction highlights an increasingly important feature of the pharmaceutical supply chain: ownership and manufacturing geography are not necessarily the same thing.
CHI operates internationally, while its new owner is headquartered in the United States.
This creates a cross-border structure in which:
U.S. private equity ownership → Global manufacturing network → International pharmaceutical customers
For procurement teams, ownership changes can matter because strategic decisions regarding capacity investment, sourcing, inventory and facility utilization may change even when manufacturing sites themselves remain in the same locations.
Pharmaceutical companies increasingly prioritize supply-chain resilience following years of logistics disruptions, geopolitical uncertainty and manufacturing concentration risks.
CHI's local-for-local manufacturing approach and broad geographic footprint are therefore strategically valuable.
Lonza has described the business as having an agile and resilient supply chain supported by manufacturing and service capabilities across regions.
Under new ownership, maintaining this geographic diversity could become an important competitive advantage.
For pharmaceutical buyers, a supplier with manufacturing options across multiple regions can reduce exposure to:
Cross-border shipping disruptions
Port congestion
Regional regulatory changes
Trade restrictions
Single-site production failures
Geopolitical disruptions
The transaction comes as pharmaceutical companies increasingly reassess sourcing strategies.
Rather than selecting suppliers purely on price, buyers are increasingly evaluating:
Cost + Quality + Capacity + Regulatory Compliance + Supply Security
Capsules and health ingredients are particularly important because interruptions can affect finished-dose pharmaceutical and nutraceutical production.
A shortage of a critical capsule specification, for example, can delay downstream manufacturing even when the active pharmaceutical ingredient is readily available.
Therefore, supplier ownership changes should be incorporated into long-term procurement risk assessments.
The acquisition could create opportunities for CHI to invest in areas where pharmaceutical and nutraceutical demand is expanding.
Lonza has highlighted several growth opportunities within oral solid dosage products, including GLP-1 therapies, peptides, live biotherapeutics and emerging oral biologics.
The growth of oral formulations is particularly significant.
Pharmaceutical companies are looking for alternatives to injectable treatments where appropriate, while patients and consumers increasingly seek convenient dosage forms.
This could support demand for advanced capsule technologies and specialized delivery systems.
CHI is also exposed to the expanding nutraceutical market.
Demand for supplements, functional ingredients and specialized delivery formats has increased the importance of capsule innovation.
Plant-based, vegetarian, vegan and clean-label capsule solutions are becoming increasingly relevant for consumer-facing brands.
For procurement teams, this means that capsule sourcing is not necessarily a standardized commodity purchase.
Material type, formulation compatibility, release profile, regulatory requirements and sustainability specifications can all influence supplier selection.
The ownership transition creates several areas that procurement teams should monitor.
Existing customers should closely review how the ownership transition affects commercial agreements, pricing mechanisms, minimum order requirements and renewal terms.
Buyers should monitor whether Lone Star invests in additional capacity or changes production allocation across facilities.
Customers should evaluate whether alternative CHI production locations can provide supply-chain flexibility.
Investment in specialized capsules and advanced dosage technologies could create new sourcing opportunities for pharmaceutical companies.
Ownership changes should be incorporated into supplier-risk assessments alongside financial, operational and regulatory indicators.
The Lonza transaction reflects a wider trend in the pharmaceutical supply chain.
Specialized manufacturing and ingredient businesses are increasingly attractive acquisition targets because they provide exposure to recurring pharmaceutical demand and technically demanding products.
At the same time, large healthcare companies are increasingly simplifying their portfolios and concentrating capital on their highest-growth businesses.
This creates a cycle:
Large strategic company divests non-core asset → Financial investor acquires specialized platform → New owner invests or restructures → Customers adapt sourcing strategies
For procurement teams, tracking these ownership changes can provide early insight into future supplier strategies.
The CHI transaction is the largest step in Lonza's transformation into a pure-play CDMO.
The company has also agreed to divest its Personalized Medicines business, the MODA software platform and its small-molecules micronization site in Monteggio.
Following these transactions, Lonza will be able to concentrate more heavily on its core CDMO platforms and pharmaceutical manufacturing capabilities.
Its Q1 2026 update showed strong demand across its CDMO business, with the company maintaining its 2026 outlook for 11–12% sales growth at constant exchange rates and a CORE EBITDA margin above 32%.
Lonza’s agreement to sell its Capsules & Health Ingredients business to Lone Star Funds represents a major change in ownership for an important global pharmaceutical and nutraceutical supply platform.
The CHF 2.3 billion transaction, combined with Lonza's retained 40% stake, allows Lonza to redirect capital toward its core CDMO strategy while giving Lone Star control of a specialized international business.
For pharmaceutical procurement teams, the transaction is more than a corporate-finance event. It could influence future investment, manufacturing capacity, product development, geographic sourcing and supplier relationships.
As the transaction moves toward its expected H2 2026 closing, customers should monitor changes in ownership, capacity, pricing, manufacturing locations and contract terms.
The broader lesson is clear: supplier ownership is becoming an increasingly important component of pharmaceutical supply-chain intelligence. Understanding who owns critical manufacturing and ingredient assets can help buyers anticipate strategic changes before they affect sourcing decisions.
Featured Product
Found this useful?
Continue Reading
PwC highlights growing capital concentration in scaled, strategic trade-exposed assets, with implications for chemical capacity
Eastman's working-capital normalization signals improving supply-chain visibility, inventory balance and trade-flow predictability for global chemical procurement.
Lone Star Funds' acquisition of Lonza's capsules business highlights investor confidence in pharmaceutical supply-chain resilience
